---
type: "Symbol"
title: "Mabwell (688062.SH) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/688062.SH/topics.md"
symbol: "688062.SH"
parent: "https://longbridge.com/en/quote/688062.SH.md"
count: 13
datetime: "2026-03-09T15:32:55.750Z"
locales:
  - [en](https://longbridge.com/en/quote/688062.SH/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688062.SH/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688062.SH/topics.md)
---

# Mabwell (688062.SH) — Community Discussions

### [Two BD transactions in a single day, stock price hits the 20cm limit-up. Has the overwhelming fortune finally come to Mabwell Biopharma?](https://longbridge.com/en/topics/31352984.md)

- Author: [医药研究社](https://longbridge.com/en/profiles/15545088.md)
- Datetime: 2025-07-01T13:05:03.000Z
- Comments: 0
- Mabwell Biopharma "made a splash". On the same day, the company announced two major BD deals. According to the announcement, Mabwell Biopharma and its wholly-owned subsidiary Taikang Biopharma

### [The innovative drug sector welcomes multiple positive news again! E Fund Innovative Drug ETF (517380) has seen continuous capital inflows for two consecutive days, while the Biopharmaceutical ETF (159859) recorded a net subscription of over 28 million during the session.](https://longbridge.com/en/topics/31220679.md)

- Author: [格隆汇](https://longbridge.com/en/profiles/11813099.md)
- Datetime: 2025-06-27T03:07:42.000Z
- Comments: 0
- Gelonghui June 27th｜Today, innovative drug concept stocks fluctuated and strengthened, with Mabwell Biopharma hitting a 20cm limit-up, Huaren Health and Jinbo Biotech rising over 10%, Biopharma ETF (1

### [$Mabwell(688062.SH)Mabwell Bio: 1- Signed an "…](https://longbridge.com/en/topics/31184204.md)

- Author: [黑眼圈吒吒](https://longbridge.com/en/profiles/12754391.md)
- Datetime: 2025-06-26T13:26:47.000Z
- Comments: 0
- $Mabwell(688062.SH)Mabwell Bio: 1- Signed an "Exclusive License Agreement" with CALICO for IL-11 targeted therapy (including 9MW3811). According to the agreement, Mabwell Bio exclusively licen

### [Behind the rise of Hong Kong stocks: the rise of the pharmaceutical industry, the divergence of large technology stocks, how to layout stocks such as Kuaishou?](https://longbridge.com/en/topics/28409907.md)

- Author: [选股男](https://longbridge.com/en/profiles/18036701.md)
- Datetime: 2025-03-27T09:49:22.000Z
- Comments: 0
- On March 27, the Hong Kong stock market closed with the Hang Seng Index up 0.41% and the Hang Seng Tech Index up 0.29%. The Hong Kong stock market opened higher in the morning session, then showed div

### [The Hong Kong IPO market remained hot in January, with 7 A-share companies rushing to list in Hong Kong.](https://longbridge.com/en/topics/27000384.md)

- Author: [财华社](https://longbridge.com/en/profiles/11651030.md)
- Datetime: 2025-02-06T02:07:39.000Z
- Comments: 0
- Last year, the market was generally optimistic about the Hong Kong IPO market in 2025, driven by factors such as the effectiveness of the reform of the Hong Kong listing mechanism. In January 2025, as

### [[IPO Frontline] Vaccine company Zhonghui Biotech rushes to list on Hong Kong stocks amid declining sector performance](https://longbridge.com/en/topics/26804984.md)

- Author: [新用户_M34nr8](https://longbridge.com/en/profiles/12238659.md)
- Datetime: 2025-01-27T08:14:28.000Z
- Comments: 0
- Recently, the Hong Kong stock market has seen several biotech companies submit listing applications, including $Biokin Pharmaceutical(688506.SH), $Hengrui Pharma(600276.SH), $Mabwell(688062.SH), and B

### [[IPO Frontline] Loss-making pharmaceutical companies on the STAR Market are venturing into the Hong Kong Stock Exchange! What's the intention of Mabwell Biotech?](https://longbridge.com/en/topics/26639628.md)

- Author: [财华社](https://longbridge.com/en/profiles/11651030.md)
- Datetime: 2025-01-16T02:50:36.000Z
- Comments: 0
- Since 2024, the A-share market has witnessed a wave of companies going to Hong Kong, $Midea Group(000333.SZ)$MIDEA GROUP(00300.HK), $SF Holding(002352.SZ)$SF HOLDING(06936.HK) , $LOPAL(603906.SH) (024

### [The global ambition of Chinese pharmaceutical companies: Not just talk](https://longbridge.com/en/topics/20499167.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2024-04-12T10:21:04.000Z
- Comments: 0
- Can you believe it? The domestic innovative drug sector is undergoing a revolutionary transformation. In March this year, a rumor exploded in the industry like spring thunder—'comprehensive support fo

### [Mabwell Biosciences, the next rising star in biotech profitability?](https://longbridge.com/en/topics/20463839.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2024-04-10T11:44:58.000Z
- Comments: 0
- The pharmaceutical market is unpredictable, with countless biotech companies trying to stand out from the fierce competition. However, Mabwell Biopharma has become the 'darling of the capital market' 

### [百奥泰的「生物类似药」春天](https://longbridge.com/en/topics/11619573.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2024-02-18T02:58:52.000Z
- Comments: 0
- 1 年 2 款生物类似药获 FDA 批准上市，另有 3 款生物类似药处于三期临床中，百奥泰迎来「生物类似药」的春天？ 012 款生物类似药，成功闯关 FDA 过去的一年，有多款国产药物成功闯关 FDA。其中，不仅有国产创新药，还有$BIO-THERA(688177.SH) 的 2 款生物类似药，包括施瑞立（托珠单抗）、普贝希（贝伐珠单抗），分别于 2023 年 10 月、12 月获 FDA 批准上

### [A 股药企股价涨幅 TOP10（2023 年）](https://longbridge.com/en/topics/10858625.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2024-01-02T12:04:04.000Z
- Comments: 0
- 尽管 2023 年 A 股医药板块尚未完全回暖，但也产生了一些牛股。据同花顺财经数据，2023 年股价涨幅最高的 10 家药企分别为：百利天恒、新诺威、通化金马、常山药业、首药控股、$Mabwell(688062.SH) 、$Allist(688578.SH) 、$Xingqi Pharmaceutical(300573.SZ) 、诺泰生物、百奥泰。其中，8 家药企全年股价涨幅超 100%，百利天

### [中国自免市场大年即将到来？](https://longbridge.com/en/topics/10562624.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2023-12-13T12:52:01.000Z
- Comments: 0
- 在全球市场，自免领域已诞生不少重磅药物。有机构预测，自免有望成为中国第二大疾病市场。尽管修美乐（阿达木单抗）未能在中国市场复制 “药王” 神话，却给行业带来了明灯式的指引作用。除竞争激烈的 TNF-α抑制剂外，目前有两趟新一代自免创新药 “列车” 供国产药企选择：一趟是 IL 类生物制剂，一趟是 JAK 小分子抑制剂。而这两趟 “列车”，将让中国自免市场驶向商业化大年...

### [ADC 洗牌战：迈威、荣昌、百利天恒、科伦博泰，谁将崛起？](https://longbridge.com/en/topics/10081400.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2023-10-03T11:21:13.000Z
- Comments: 0
- PD-1、ADC 都是严重内卷的领域，洗牌潮已经来临，而突围的关键就在于 “差异化”。相较于 PD-1 单抗，ADC 的差异化之路更为多元：可选择差异化的靶点，可布局新技术、新适应症，也可拓展新思路（如双抗 ADC、ADC 联合疗法等）。 一、ADC 赛道涌现潜力靶点：CLDN18.2、Nctin-4、B7-H3/B7-H4 在 ADC 药物靶点中，HER2 赛道是拥挤程度最高的...

## References

- [Mabwell (688062.SH)](https://longbridge.com/en/quote/688062.SH.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688062.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688062.SH/topics.md)